PROGRAM DESCRIPTION
The Master of Science in Biotechnology program in the College of Medicine will prepare students to function in the industrial biotechnology environment. This program is designed to give students broad knowledge and training in the scientific and practical aspects of biotechnology.
The Master of Science in Biotechnology program in the College of Medicine will prepare students to function in the industrial biotechnology environment. This program is designed to give students broad knowledge and training in the scientific and practical aspects of biotechnology.
It involves innovative, hands-on and multidisciplinary learning approaches to educate and train students in scientific aspects of biotechnology. The courses and research training required of all students in this program are designed to develop independent thinking, team work and communication skills, which are highly desirable in the biotechnology industry. Students will be provided an industrial perspective and an understanding of product development at the same time as they are trained in the biotechnology techniques required for such development.
The Master of Science in Biotechnology program consists of a minimum of 30 semester credit hours of graduate courses offeredby the Burnett School of Biomedical Sciences inthe College of Medicine that includes 21 credit hours minimum of required courses, 3 credits of restricted electives,and 6 credit hours of thesis research as detailed below.
What makes this program unique is the focus on practical training offered to graduate students through masters thesis research in molecular biotechnology to perform jobs in laboratory environment that require scientific talent.
Students must take the following courses plus at least two credit hours of graduate seminar.
MCB 5722C Methods in Biotechnology (4 credit hours) or BSC 6407C Laboratory Methods in Molecular Biology (3 credit hours)
BSC 6432 Structure-Function-Relationships of Biomedical Sciences I (5 credit hours)
BSC 6433 Structure-Function-Relationships of Biomedical Sciences II (5 credit hours)
BSC 6431 Practice of Biomedical Sciences (3 credit hours)
PCB 5527 Genetic Engineering and Biotechnology (3 credit hours) or one of the following: BSC 5418 Tissue Engineering (3 credit hours), MCB 6417C Microbial Metabolism (3 credit hours), PCB 5025 Molecular and Cellular Pharmacology (3 credit hours)
Students will participate in at least two graduate seminar courses thatwill prepare them for making professional presentations with emphasis in biotechnology. The courseswill involve participation of speakers from the biotechnology industry with emphasis on an industrial perspective on biotechnology applications and product development.
Students willselect three credit hours of restricted electives from the list below.
Students will take a minimum of six credits of thesis research (MCB 6971) to complete their research and submit their thesis specializing in biotechnology research. Students are expected to have an in-depth discussion with at least three faculty members before choosing alaboratory for thesis research.The student and the Thesis Adviser/Major Professor will jointly recommend an advisory committee comprised of at least three members. The committee composition must reflect expertise relevant to the students thesis research and must be approved by the Graduate Committee. Students switching to change the composition of the Thesis Advisory Committee must also obtain approval from the Graduate Committee.
The thesis proposal defense requirement should be met and passed successfully no later than the end of the summer of the first year in the program. Students will not be allowed to register for courses for the Fall semester of their second year until this requirement is fulfilled. The Thesis Proposal requirement includes: 1) a written 5-page thesis proposal; 2) a thesis proposal defense in front of the thesis committee; and 3) questions by the thesis committee to test the student's understanding of the basic concepts in the field and relevant applications. The student will be evaluated on performance in all three sections. Should the student fail, a second opportunity will be provided within 2 weeks of the first attempt. A second failure will result in dismissal from the program.
An oral thesis defense is required. The defense will be in the format of:
A 50-minute presentation of the thesis work, including a 5-minute introduction
A 10-minute free period for the general audience to ask questions
A 1-hour closed-door examination by the Thesis Advisory Committee and the program faculty present
The thesis should be of significant scope and depth such that the work has made advances in the area of biotechnology. The MS thesis research must generate sufficient quantity and quality data to support the submission of a minimum of one manuscript. Approval of the final thesis will require consent from the majority of the Program Faculty who choose to review the thesis, inclusive of the Thesis Advisory Committee. Faculty members with dissenting vote on the thesis must provide written justification. Scientific journal review criteria will be used as guidelines by the faculty to evaluate the final thesis for its appropriateness for publication in the target journal.
Students will be evaluated on the progress in thesis research by the thesis advisory committee for fall and spring. Two consecutive unsatisfactory evaluations will result in dismissal from the program.
Students must pass a comprehensive exam to qualify for the Master of Science degree.
Students must successfully pass an oral comprehensive examination to test the understanding of the basic concepts in the field and relevant applications. The Comprehensive Examination will be conducted during the thesis proposal defense.The exam will be administered by the thesis committee. Should the student fail this exam, a second opportunity will be provided within 2 weeks of the first attempt. A second failure will result in dismissal from theprogram.
For information on general UCF graduate admissions requirements that apply to all prospective students, please visit theAdmissions section of the Graduate Catalog.Applicants mustapply online. All requested materials must be submitted by the establisheddeadline.
In addition to thegeneral UCF graduateapplication requirements, applicants to this program must provide:
Personal interviews are helpful but not required. Applicants whodo not have a competitiveGPA or GRE may occasionally be accepted if there is other convincing evidence of potential for high achievement and success.
Applicants who hold a BS degree in unrelated fields are expected to have the equivalent of 16 semester hours of credit in the biotechnology/biological sciences including a course in general microbiology, biochemistry or molecular biology or cell biology, plus one year of organic chemistry, one year of physics, basic university mathematics and statistics, and laboratory skills equivalent to the minimum required of our own undergraduates. Minor deficiencies may be remedied after acceptance by enrollment at the first opportunity in an appropriate course.
-
-
-
-
-
-
Fellowships are awarded based on academic merit to highly qualified students. They are paid to students through the Office of Student Financial Assistance, based on instructions provided by the College of Graduate Studies. Fellowships are given to support a students graduate study and do not have a work obligation. For more information, see UCF Graduate Fellowships, whichincludes descriptions of university fellowshipsand what you should do to be considered for a fellowship.
Read more:
Biotechnology MS Degree - UCF Graduate Catalog 2016-2017
- Biotechnology / Pharmaceutical Services Outsourcing Business Report 2024-2030: Expansion of Clinical Trials and Need for Regulatory Compliance... - May 17th, 2025
- Biotechnology Market Size 2025: Innovations, Growth Opportunities, and Industry Outlook | CAGR of 12.3% - openPR.com - May 17th, 2025
- Nestl strengthens R&D with new biotechnology and deep tech initiatives - FoodBev Media - May 17th, 2025
- PeptiSystems and Asahi Kasei launch exclusive partnership on peptides - The Pharma Letter - May 17th, 2025
- Genentech expands to North Carolina with $700 million facility, add over 400 new jobs; company based in San Francisco - ABC11 - May 17th, 2025
- Anbio Biotechnology to Showcase Innovative Diagnostic Solutions at Key International Exhibitions in May 2025 - Nasdaq - May 17th, 2025
- SANA Investors Have Opportunity to Lead Sana Biotechnology, Inc. Securities Fraud Lawsuit with the Schall Law Firm - Morningstar - May 17th, 2025
- India at the Forefront of Biotechnology and Innovation - OpenGov Asia - May 17th, 2025
- Biotechnology catches up with the "water bear": tattoos created on nearly indestructible creatures - drivingeco.com - May 17th, 2025
- Researchers at Keralas Rajiv Gandhi Centre for Biotechnology discover method to target drug-resistance i - Times of India - May 17th, 2025
- NSF Funding is Key to the Biotechnology Workforceand National Security - New America - May 6th, 2025
- Matica Biotechnology and Texas A&M's NCTM Form Strategic Partnership to Deliver End-to-End Support for Cell and Gene Therapy Innovators - PR Newswire - May 6th, 2025
- Shareholders that lost money on Sana Biotechnology, Inc.(SANA) Urged to Join Class Action - Contact The Gross Law Firm to Learn More - PR Newswire - May 6th, 2025
- ETSU helps shape the future of U.S. biotechnology - East Tennessee State University - May 6th, 2025
- Matica Biotechnology and Texas A&M's NCTM Form Strategic Partnership to Deliver End-to-End Support for Cell and Gene Therapy Innovators - Citizen... - May 6th, 2025
- Halozyme to Participate in the BofA Securities 2025 Healthcare Conference - Quantisnow - May 6th, 2025
- Red Biotechnology Market to Witness Remarkable Growth with - openPR.com - May 6th, 2025
- Enabling next-generation anaerobic cultivation through biotechnology to advance functional microbiome research - Nature - May 6th, 2025
- Sana Biotechnology, Inc. Class Action: Levi & Korsinsky Reminds Sana Biotechnology, Inc. Investors of the Pending Class Action Lawsuit with a Lead... - May 6th, 2025
- Epicrispr Biotechnologies Announces Five Presentations Highlighting Advances in Epigenetic Modulation and AAV Manufacturing at ASGCT 2025 Annual... - May 6th, 2025
- Protalix BioTherapeutics to Announce First Quarter 2025 Financial and Business Results on May 9, 2025 - Quantisnow - May 6th, 2025
- Opinion: Canada should invest in itself instead of subsidizing foreign biotechnology companies - The Globe and Mail - April 14th, 2025
- National Commission Outlines Six Ways to Turbocharge U.S. Biotech Innovation Against the Threat from China - Genetic Engineering and Biotechnology... - April 14th, 2025
- Cereno Scientific to attend BIO International Convention 2025 - largest and most comprehensive event for biotechnology - TradingView - April 14th, 2025
- The Future of Plant Biotechnology Services: Market Expected to Reach USD 42.07 Billion by 2032 with 12.8% CAGR - openPR.com - April 14th, 2025
- Understanding the National Security Commission on Emerging Biotechnology Report - CSIS | Center for Strategic and International Studies - April 14th, 2025
- Congressional commission urges $15B, more action to maintain US biotech advantage over China - Fierce Biotech - April 14th, 2025
- Novonesis Poised to Accelerate National Security Commission Priorities on Biotechnology - PR Newswire - April 14th, 2025
- Class Action Filed Against Sana Biotechnology, Inc. (SANA) Seeking Recovery for Investors - Contact Levi & Korsinsky - PR Newswire - April 14th, 2025
- The Future of Mining with AI and Biotechnology Solutions - MSN - April 14th, 2025
- Padilla, Congressional Biotech Commission Introduce Bipartisan Bill to Bolster U.S. Biotechnology Innovation and Economy - Senator Alex Padilla (.gov) - April 14th, 2025
- US commission says $15B biotech investment is needed to maintain dominance over China - FirstWord Pharma - April 14th, 2025
- Senator Young Warns of Biotechnology Competition with China - WIBC - April 14th, 2025
- Research shows need for better mpox protection in HIV-positive patients - The Pharma Letter - April 5th, 2025
- Marine Biotechnology Market to Reach $10.37 Bn by 2032 with 6.2% CAGR - openPR.com - April 5th, 2025
- Robbins LLP Reminds SANA Investors with Large Losses to Contact the Firm for Information About the Securities Fraud Class Action Against Sana... - April 5th, 2025
- Crescent Biopharma Appoints Joshua Brumm as Chief Executive Officer and Expands Leadership Team to Advance Pipeline of Potentially Best-in-Class... - April 5th, 2025
- Tech Trends 2030: How AI, Quantum Computing, and Biotechnology Will Shape the Future - Analytics Insight - February 24th, 2025
- The Security Implications of Developments in Biotechnology - International Institute for Strategic Studies - February 24th, 2025
- Biotechnology Permits and Notifications - USDA APHIS - February 24th, 2025
- Sustained in situ protein production and release in the mammalian gut by an engineered bacteriophage - Nature.com - February 24th, 2025
- Internal cap-initiated translation for efficient protein production from circular mRNA - Nature.com - February 24th, 2025
- MIT class takes students on a grand tour of the interdisciplinary world of biotech - MIT News - February 24th, 2025
- BioTech Breakthrough Awards BostonGene With Cancer Immunology Solution of the Year - Business Wire - February 24th, 2025
- Biodiversity to Bioeconomy - PIB - February 24th, 2025
- Luxa Biotechnology Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to RPESC-RPE-4W Transplantation for the Treatment... - February 24th, 2025
- Biofach 2025: Biosan Biotechnology CEO talks popular mushroom blends and wellness benefits - Nutrition Insight - February 24th, 2025
- Pushing the boundaries of biotechnology - UC Santa Cruz - January 27th, 2025
- Living with the Land Biotechnology Lab Now Blocked by Scrims & More: Daily Recap (1/26/25) - WDW News Today - January 27th, 2025
- Living with the Land Biotechnology Lab Now Blocked by Scrims in EPCOT - WDW News Today - January 27th, 2025
- Biotechnology led to dramatic innovations in agriculture and human health in 2024 - Genetic Literacy Project - January 27th, 2025
- Cultured algae and biotechnology are ingredients to the 'Gelato of the future' - STIRworld - January 27th, 2025
- New U.S. Export Controls Seek to Prevent China From Weaponizing Biotech - Foundation for Defense of Democracies - January 27th, 2025
- Fresh from the biotech pipeline: FDA approvals settle in 2024, but what next? - Nature.com - January 27th, 2025
- Nuevocor Welcomes Andreas Wallnfer as Chairman of the Board of Directors - Kilgore News Herald - January 27th, 2025
- Creating and sustaining university biotech spin-outs - PMLiVE - January 27th, 2025
- IMTECH celebrates 41st foundation day with focus on BioE3 policy and biotechnology innovations - The Times of India - January 27th, 2025
- What's Going On With Liver Disease Focused Vir Biotechnology Stock Is Friday? - Yahoo Finance - November 16th, 2024
- Department of Biotechnology Launches Webinar Series on Biomanufacturing and Biofoundry Initiative - IBG NEWS - November 16th, 2024
- Multimodal scanning of genetic variants with base and prime editing - Nature.com - November 16th, 2024
- NEW INITIATIVE BY THE ITALIAN EMBASSY IN WASHINGTON ON BIOTECHNOLOGY WITH THE MILKEN INSTITUTE AND LEADING RESEARCHERS AND INDUSTRY EXPERTS -... - November 16th, 2024
- Vir Biotechnology Announces Positive End-of-Treatment Results for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B from the MARCH Study at... - November 16th, 2024
- Albany State offers new Master of Science in Integrated Biotechnology program - The Albany Herald - November 16th, 2024
- What's Going On With Liver Disease Focused Vir Biotechnology Stock Is Friday? - Benzinga - November 16th, 2024
- iNtRON Biotechnology (KOSDAQ:048530) Is In A Strong Position To Grow Its Business - Simply Wall St - November 16th, 2024
- PDS Biotechnology Highlights Clinical Progress and Q3 Results - TipRanks - November 16th, 2024
- We Think Puma Biotechnology's (NASDAQ:PBYI) Robust Earnings Are Conservative - Yahoo Finance - November 16th, 2024
- Puma Biotechnology's (NASDAQ:PBYI) Performance Is Even Better Than Its Earnings Suggest - Simply Wall St - November 16th, 2024
- APHIS Announces Final Notice on Additional Exemptions for the Movement of Organisms Modified or Produced Through Genetic Engineering - USDA APHIS - November 16th, 2024
- Adaptimmune nears second approval for TCR-T therapy - European Biotechnology News - November 16th, 2024
- Lundbeck reports 18% revenue growth in third quarter - The Pharma Letter - November 16th, 2024
- BioNTech to boost oncology offering with buy of Biotheus - The Pharma Letter - November 16th, 2024
- Puma Biotechnology Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance - November 16th, 2024
- WPI Receives Federal Funding to Address Anticipated Demand for Biology and Biotechnology Professionals and Educators - WPI News - November 3rd, 2024
- Jonathan Dinman to Direct the Institute for Bioscience and Biotechnology Research - College of Computer, Mathematical, and Natural Sciences - November 3rd, 2024
- PDS Biotechnology Co. (NASDAQ:PDSB) Given Average Recommendation of "Buy" by Analysts - MarketBeat - November 3rd, 2024
- COP16, DSI mechanism for benefit sharing from the use of digital sequence information approved - Renewable Matter - November 3rd, 2024
- Artificial Intelligence in Biotechnology Market to Hit USD 7.75 Billion by 2029 with 19.1% CAGR | MarketsandMarkets - PR Newswire - November 3rd, 2024
- Axonis Therapeutics raises $115 million in Series A financing - The Pharma Letter - November 3rd, 2024
- Regeneron third-quarter 2024 earnings top expectations - The Pharma Letter - November 3rd, 2024